Khan Hamid, Mubarak Muhammed, Aziz Tahir, Ahmed Ejaz, Fazal Akhter Syed, Kazi Javed, Aa Naqvi Syed, Ah Rizvi Syed
Department of Nephrology, Sindh Institute of Urology and Transplantation (SIUT) Karachi, Pakistan.
Department of Histopathology, Sindh Institute of Urology and Transplantation (SIUT) Karachi, Pakistan.
J Nephropathol. 2014;3(2):69-79. doi: 10.12860/jnp.2014.15. Epub 2014 Apr 1.
Chronic allograft nephropathy (CAN) is a common cause of delayed allograft failure throughout the world. Its prevalence and risk factors vary depending on a number of factors. There is little information on the prevalence and risk factors for early CAN in live related renal transplant patients.
We aimed to determine the prevalence and the risk factors of early CAN in our setup.
The study was conducted at Sindh Institute of Urology & Transplantation (SIUT), Karachi, from 2002 to 2005 on patients who had live related kidney transplantation and underwent at least one allograft biopsy within 18 months of transplantation. The biopsies were performed and prepared in accordance with established indications and guidelines. The Banff 97 classification and its updates were used to diagnose and categorize the biopsy pathology. Patients were divided into two groups depending on the presence or absence of CAN on biopsies. Following parameters were compared among the groups: age, sex, human leukocyte antigen (HLA) match, immunosuppression used, acute rejection (AR) episodes, urinary tract infections (UTIs), viral infections, cyclosporine levels, early and late graft function monitored by serum creatinine.
A total of 164 patients fulfilled the study inclusion criteria. The mean age of recipients and donors was relatively young. The majority of the donors were siblings. The overall prevalence of CAN was 25.6% (42/164), between 3 and 18 months post transplantation. The median time to the appearance of CAN was 9 months post-transplant. The prevalence of CAN increased as post-transplant duration increased. In 39 (92.8%) subjects, CAN was detected on the second or subsequent graft biopsy. Only 3 (7.2%) patients showed CAN on the first graft biopsy. The majority of cases belonged to moderate degree or grade II CAN. The mean serum creatinine values were higher in the CAN group at the time of discharge and all times post-transplantation.
In conclusion, the results show that serum creatinine at the time of discharge is a useful predictor of later development of chronic changes in the allograft. Further studies are needed to identify the risk factors for the early development of chronic changes in living related renal transplant program.
慢性移植肾肾病(CAN)是全球移植肾延迟失功的常见原因。其患病率和危险因素因多种因素而异。关于亲属活体肾移植患者早期CAN的患病率和危险因素的信息较少。
我们旨在确定我们机构中早期CAN的患病率和危险因素。
本研究于2002年至2005年在卡拉奇的信德泌尿与移植研究所(SIUT)对接受亲属活体肾移植且在移植后18个月内至少进行过一次移植肾活检的患者进行。活检按照既定的指征和指南进行操作与标本制备。采用Banff 97分类法及其更新版本对活检病理进行诊断和分类。根据活检时是否存在CAN将患者分为两组。对两组患者的以下参数进行比较:年龄、性别、人类白细胞抗原(HLA)配型、使用的免疫抑制方案、急性排斥反应(AR)发作次数、尿路感染(UTI)、病毒感染、环孢素水平,以及通过血清肌酐监测的移植肾早期和晚期功能。
共有164例患者符合研究纳入标准。受者和供者的平均年龄相对较轻。大多数供者为兄弟姐妹。移植后3至18个月期间,CAN的总体患病率为25.6%(42/164)。CAN出现的中位时间为移植后9个月。CAN的患病率随移植后时间的延长而增加。在39例(92.8%)受试者中,在第二次或后续移植肾活检时检测到CAN。只有3例(7.2%)患者在首次移植肾活检时显示有CAN。大多数病例属于中度或II级CAN。出院时及移植后所有时间,CAN组的平均血清肌酐值均较高。
总之,结果表明出院时的血清肌酐是移植肾后期慢性变化发展的有用预测指标。需要进一步研究以确定亲属活体肾移植项目中慢性变化早期发生的危险因素。